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A recent paper in The Journal of Clinical Investigation (JCI) entitled
``Antibodies against keratinocyte antigens other than desmogleins 1
and 3 can induce pemphigus vulgaris [PV]-like lesions'' calls into
question the ability of antidesmoglein (Dsg) antibodies to cause
blisters in pemphigus patients (Nguyen et al, 2000). These
conclusions are based on studies in which antibodies were passively
transferred into Dsg3null mice. In this and other papers, Dr. Sergei
Grando and his colleagues go even further to conclude that anti-
Dsg antibodies alone do not cause the blisters, but require
additional antibodies to cholinergic receptors (Nguyen et al,
1998, 2000), and conclude that ``Therefore, mucocutaneous lesions
in PV patients could be caused by non-Dsg antibodies'' (Nguyen et
al, 2000). The commentary accompanying this last paper, entitled
``Pemphigus vulgaris: the other half of the story'', tends to validate
these conclusions.
In spite of these provocative conclusions, there is no evidence
presented in this JCI paper (or the others) that non-Dsg antibodies
produce pemphigus lesions in normal mice or humans, because all
passive transfer experiments that resulted in blisters were performed
with Dsg 3null mice, which already have altered adhesion. If
anything, such experiments con®rm the importance of inactivating
Dsg3 to produce PV-like blisters.
Whereas there is little, if any, evidence regarding anticholinergic
receptor or other non-Dsg antibodies in the pathogenesis of
pemphigus, there is abundant evidence, from multiple laboratories,
that desmogleins and antidesmoglein antibodies are directly
involved in causing blisters in PV and pemphigus foliaceus (PF),
without additional non-Dsg antibodies. This evidence can be
summarized as follows:
1 Patients with PF have anti-Dsg1 antibodies (Stanley et al, 1986;
Olague-Alcala et al, 1994; Kowalczyk et al, 1995; Ishii et al, 1997;
Hashimoto et al, 1990).
2 Patients with PV have anti-Dsg3 antibodies, and greater than
50% of PV patients have, in addition, anti-Dsg1 antibodies (Ishii et
al, 1997; Hashimoto et al, 1990; Amagai et al, 1991, 1996; Lenz et
al, 1999; Eyre and Stanley 1988; Ding et al, 1997).
3 Patients with PV limited to mucous membranes (a common
clinical scenario) usually have only anti-Dsg3 antibodies (Ishii et al,
1997; Ding et al, 1997; Amagai et al, 1999).
4 PV patients who develop extensive skin involvement in addition
to oral involvement develop anti-Dsg1 antibodies in addition to
anti-Dsg3 antibodies (Ishii et al, 1997; Amagai et al, 1999;
Miyagawa et al, 1999).
5 Passive transfer studies in neonatal mice con®rm the ®ndings in
humans that both anti-Dsg3 and anti-Dsg1 antibodies are necessary
for ef®cient PV blister formation in skin. In this neonatal mouse
model of pemphigus, PV sera with anti-Dsg3 alone are much less
ef®cient at causing skin blisters than those with anti-Dsg3 and anti-
Dsg1 (Mahoney et al, 1999). Furthermore, addition of small
amounts of anti-Dsg1 antibodies from PF sera dramatically enhance
the formation of PV skin blisters caused by PV sera containing only
anti-Dsg3 antibodies (Mahoney et al, 1999). Similarly in Dsg3±/±
mice, only anti-Dsg1 antibodies are needed to cause severe PV skin
blisters, because Dsg3 is already inactivated genetically (Mahoney et
al, 1999). Grando and colleagues refute this point with the
awkward argument that previous authors have confused the
suprabasilar blister in these mice with a subcorneal blister.
However, all one has to do is examine the ®gures from the
relevant paper (Mahoney et al, 1999; Fig 3a, c show that PF IgG
causes a subcorneal blister in normal mice but a suprabasilar blister
in Dsg3null mice) to conclude that Grando's argument is fallacious.
6 Inactivation of Dsg3 by genetic means causes lesions in mice that
are strikingly similar to those seen in pemphigus patients with anti-
Dsg3 (without anti-Dsg1) antibodies, namely, suprabasilar blisters
in mucous membranes (oral and vaginal) but minimal involvement
of skin (Koch et al, 1997).
7 Inactivation of Dsg1 by exfoliative toxin A produced by
Staphylococcus aureus causes lesions in neonatal mice and humans
that are clinical and histologically similar, if not identical, to those
seen in PF (Amagai et al, 2000a).
Points 6 and 7 conclusively demonstrate that inactivation of Dsgs
alone cause pemphigus lesions, i.e., no other factor from pemphigus
sera is necessary. Point 5 demonstrates that even if Dsg3 is
inactivated by genetic means, addition of anti-Dsg1 antibodies
results in typical PV lesions of the skin, identical to those caused by
PV sera with both anti-Dsg3 and anti-Dsg1 antibodies.
8 Pathogenic activity can be adsorbed from PF and PV sera by the
extracellular domains of Dsg1 and Dsg3, respectively (Amagai et al,
1994, 1995). Grando and his colleagues use tortuous reasoning to
explain why this result does not prove that anti-Dsg3 antibodies are
pathogenic. They claim that the chimeric molecule Dsg3-Ig-His
(extracellular domain of Dsg3 with the Fc fragment of IgG and a
His tag) is able to adsorb pathogenic activity from PV sera, not
because it adsorbs anti-Dsg3 antibodies, but because it also adsorbs
other, unrelated, pathogenic antibodies. They hypothesize that
these other pathogenic antibodies (presumably anticholinergic
antibodies) are adsorbed because the Ig portion of the chimeric
molecule causes a change in con®rmation of the Dsg3. To validate
this hypothesis, Grando et al claim that the extracellular domain
without the Ig portion (Dsg3-His) will not adsorb pathogenic
activity, although they present no evidence to support this claim
and the only evidence in the literature suggests that Dsg3-His alone
adsorbs all antikeratinocyte cell surface antibodies (Ishii et al, 1997),
and that the adsorbed antibodies are pathogenic (Ding et al, 1999).
Grando and colleagues are forced to hypothesize that Dsg1-Ig-His
also, coincidentally, adsorb out these other non-Dsg pathogenic
antibodies from PF sera.
9 Dsg3null mice can be immunized with Dsg3 to produce anti-
Dsg3 antibodies that cause typical PV lesions when transferred to
Dsg3+/+ mice (again, mostly oral, as in PV patients with only anti-
Dsg3 antibodies) (Amagai et al, 2000b).
These data, from different laboratories, using different ap-
proaches, clearly support the role of desmogleins in the
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pathophysiology of pemphigus. Although Dr. Grando and his
collaborators have made some interesting and signi®cant observa-
tions about cholinergic receptors in keratinocytes and their
adhesion, they have not presented convincing evidence for their
role in the pathogenesis of pemphigus. In other words, ``the other
half of the story'', the signi®cance of these non-Dsg antibodies to
the pathophysiology of pemphigus, remains to be proved.
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